← Back to headlines
AstraZeneca Investors Express Concerns Over Potential Bristol Myers Squibb Merger
AstraZeneca investors are raising concerns and seeing little logic in a potential $400 billion mega-merger with Bristol Myers Squibb, which would create a pharmaceutical giant. Shares of AstraZeneca slumped amidst the merger rumors, with analysts questioning the strategic rationale.
3 Aug, 16:14 — 3 Aug, 17:17
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (79/100)7 sources33/33
Spectrum spread— 4/5 buckets covered25/33
Far L1
Far Left (1)
The Independent
Left1
Left (1)
Yahoo
Center2
Center (2)
bloombergFT
Right3
Right (3)
fazsvenska-dagbladetle-figaro
Far R
Geographic diversity— 5 regions21/34
US2UK2Germany1Sweden1France1
Sources
Showing 4 of 7 sources
bloombergHigh8h ago
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. (Source: Bloomberg)
Read full article →FTVery High8h ago
AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs
Read full article →The IndependentMostly Factual8h ago
Stocks mixed as AstraZeneca merger talk dents FTSE 100
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
By Jeremy Cutler
Read full article →YahooMostly Factual7h ago
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
Read full article →Coverage Timeline
First report: le-figaro · 3 Aug, 08:56|Full coverage: 7 · 8h|Window: 8h
Left-leaningCenterRight-leaning
